Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

The goal of this clinical research study is to assess the safety, tolerability, immune response, and preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine (GAd20-209-FSP prime, and MVA-209-FSP boost) and pembrolizumab.

StATins Use in intRacerebral hemorrhage patieNts (SATURN)

The study will look at patients with spontaneous intracranial hemorrhage while taking statins. The patient will then be randomized to continue or discontinue statin therapy to continue to treat the patient after the initial event.

Perimenopause and Brain Aging in Alzheimer's Disease

The purpose of this study is to better identify and predict individuals at risk for Alzheimer's disease (AD) who are most likely to benefit from personalized, evidence-based interventions. Studies have shown that endocrine aging (menopause, perimenopause) increases Alzheimer’s disease risk specifically in women. Our goal is to unravel the biological mechanisms behind the increased risk by analyzing how various measures of brain function, biochemistry, laboratory values, and other risk factors may influence Alzheimer’s risk as women age.

Utilizing Smartphone Applications in Parkinson's Disease Management

The purpose of this study is to test whether active tasks completed on a personal smartphone are feasible as an approach to collecting data from patients with movement disorders. In particular, we are investigating whether it is a user-friendly interface for patients with movement disorders. The active tasks that participants will complete measure dexterity and speed, which are major components of the Unified Parkinson’s Disease Rating Scale and Movement Disorder Society Scales.

Identifying mechanisms of tissues injury in MS lesions: a multi-modality imaging approach

Effective treatment to prevent disability MS has been largely non-existent due to a poor understanding of the relevant pathophysiologic mechanisms. The purpose of the study is use novel PET and MRI techniques to study acute multiple sclerosis (MS) lesion. We will use a Magnetic Resonance Imaging (MRI) imaging sequence (programmed set of parameters and magnetic gradients) which will measure myelin and iron within lesions. Positron Emission Tomography (PET) is another test which may be more detailed information about factors causing damage within MS lesions. MRI is a test approved by FDA.

Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)

This study aims to determine if apixaban is superior to aspirin for prevention of stroke or hemorrhage or death in patients with recent intracerebral hemorrhage or atrial fibrillation.

Biochemical characterization of Parkinson's disease-related proteins in the enteric nervous system

Parkinson's disease affects 1 in 100 people over the age of 65, but the time between Parkinson's disease onset and diagnosis can be many months or years. Interestingly, pathological hallmarks of Parkinson's in the brain can also be seen in the neurons in the gut and symptoms like constipation often precede the onset of tremor and incoordination by many years. It is now believed that Parkinson's disease may begin in the gut, at least in some people.

MRI Detection of Carotid Plaques as a mechanism for embolic strokes of undetermined source (MRI DECIPHER)

The study is investigating a link between high-risk plaque and cardioembolic sources among patients with stroke of unknown causes. This observational study uses an MRI protocol to detect bleeds within plaque, a marker of high-risk plaque. There is an additional PET/MRI that patients can opt into to more closely observe the plaque within the carotid arteries.

This study includes optional parts which will have financial compensation.

Converting HR+ Breast Cancer Into An Individualized Vaccine

Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible for this randomized trial that will be concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of the trial testing focal hypo-fractionated RT alone or with immunotherapy combinations.